BACKGROUND: The MTHFR C677T TT genotype is associated with a 15% to 18% reduction in colorectal cancer risk, but it is not clear if other variants of the gene are associated with colorectal cancer risk. METHODS: We used a tagSNP approach to comprehensively evaluate associations between variation in the MTHFR gene and colorectal cancer risk using a large family-based case-control study of 1,750 population-based and 245 clinic-based families from the Colon Cancer Family Registry. We assessed 22 TagSNPs, selected based on pairwise r(2) >95%, using the Haploview Tagger and genotyped the TagSNPs on the Illumina GoldenGate or Sequenom platforms. The association between single nucleotide polymorphisms and colorectal cancer was assessed using log-additive, codominant, and recessive models. RESULTS: From studying the population-based families, the C677T (rs1801133) and A1298C (rs1801131) polymorphisms were associated with a decreased colorectal cancer risk overall [odds ratio (OR), 0.81; 95% confidence interval (95% CI), 0.63-1.04; and OR, 0.82; 95% CI, 0.64-1.07, respectively]. The 677 TT genotype was associated with a decreased risk of microsatellite-stable/microsatellite-low tumors (OR, 0.69; 95% CI, 0.49-0.97) and an increased risk of microsatellite-high tumors (OR, 2.22; 95% CI, 0.91-5.43; P(interaction) = 0.01), as well as an increased risk of proximal cancers and a decreased risk of distal and rectal cancers (P(interaction) = 0.02). No other single nucleotide polymorphism was associated with risk overall or within subgroups. CONCLUSION: The 677 TT and 1298 CC genotypes may each be associated with a decrease in colorectal cancer risk. We observed little evidence of additional genetic variability in the MTHFR gene relevant to colorectal cancer risk.
BACKGROUND: The MTHFR C677T TT genotype is associated with a 15% to 18% reduction in colorectal cancer risk, but it is not clear if other variants of the gene are associated with colorectal cancer risk. METHODS: We used a tagSNP approach to comprehensively evaluate associations between variation in the MTHFR gene and colorectal cancer risk using a large family-based case-control study of 1,750 population-based and 245 clinic-based families from the Colon Cancer Family Registry. We assessed 22 TagSNPs, selected based on pairwise r(2) >95%, using the Haploview Tagger and genotyped the TagSNPs on the Illumina GoldenGate or Sequenom platforms. The association between single nucleotide polymorphisms and colorectal cancer was assessed using log-additive, codominant, and recessive models. RESULTS: From studying the population-based families, the C677T (rs1801133) and A1298C (rs1801131) polymorphisms were associated with a decreased colorectal cancer risk overall [odds ratio (OR), 0.81; 95% confidence interval (95% CI), 0.63-1.04; and OR, 0.82; 95% CI, 0.64-1.07, respectively]. The 677 TT genotype was associated with a decreased risk of microsatellite-stable/microsatellite-low tumors (OR, 0.69; 95% CI, 0.49-0.97) and an increased risk of microsatellite-high tumors (OR, 2.22; 95% CI, 0.91-5.43; P(interaction) = 0.01), as well as an increased risk of proximal cancers and a decreased risk of distal and rectal cancers (P(interaction) = 0.02). No other single nucleotide polymorphism was associated with risk overall or within subgroups. CONCLUSION: The 677 TT and 1298 CC genotypes may each be associated with a decrease in colorectal cancer risk. We observed little evidence of additional genetic variability in the MTHFR gene relevant to colorectal cancer risk.
Authors: D O Stram; J H Hankin; L R Wilkens; M C Pike; K R Monroe; S Park; B E Henderson; A M Nomura; M E Earle; F S Nagamine; L N Kolonel Journal: Am J Epidemiol Date: 2000-02-15 Impact factor: 4.897
Authors: Giuseppe Toffoli; Roberta Gafà; Antonio Russo; Giovanni Lanza; Riccardo Dolcetti; Franca Sartor; Massimo Libra; Alessandra Viel; Mauro Boiocchi Journal: Clin Cancer Res Date: 2003-02 Impact factor: 12.531
Authors: Barry Iacopetta; Jane Heyworth; Jennifer Girschik; Fabienne Grieu; Cassandra Clayforth; Lin Fritschi Journal: Int J Cancer Date: 2009-07-01 Impact factor: 7.396
Authors: Elizabeth A Hibler; Chengcheng Hu; Peter W Jurutka; Maria E Martinez; Elizabeth T Jacobs Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-12-05 Impact factor: 4.254
Authors: Kathryn L Terry; Shelley S Tworoger; Ellen L Goode; Margaret A Gates; Linda Titus-Ernstoff; Linda E Kelemen; Thomas A Sellers; Susan E Hankinson; Daniel W Cramer Journal: Gynecol Oncol Date: 2010-11 Impact factor: 5.482
Authors: A Joan Levine; Jane C Figueiredo; Won Lee; David V Conti; Kathleen Kennedy; David J Duggan; Jenny N Poynter; Peter T Campbell; Polly Newcomb; Maria Elena Martinez; John L Hopper; Loic Le Marchand; John A Baron; Paul J Limburg; Cornelia M Ulrich; Robert W Haile Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-07 Impact factor: 4.254
Authors: Brenna L Seufert; Elizabeth M Poole; John Whitton; Liren Xiao; Karen W Makar; Peter T Campbell; Richard J Kulmacz; John A Baron; Polly A Newcomb; Martha L Slattery; John D Potter; Cornelia M Ulrich Journal: Carcinogenesis Date: 2012-09-22 Impact factor: 4.944
Authors: Sarah E Kleinstein; Laura Heath; Karen W Makar; Elizabeth M Poole; Brenna L Seufert; Martha L Slattery; Liren Xiao; David J Duggan; Li Hsu; Karen Curtin; Lisel Koepl; Jill Muehling; Darin Taverna; Bette J Caan; Christopher S Carlson; John D Potter; Cornelia M Ulrich Journal: Genes Chromosomes Cancer Date: 2013-02-12 Impact factor: 5.006
Authors: Elizabeth A Hibler; Elizabeth T Jacobs; Angelika Dampf Stone; Christine L Sardo; Michael A Galligan; Peter W Jurutka Journal: Cancer Prev Res (Phila) Date: 2014-01-28